KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Receivables - Other (2016 - 2020)

Historic Receivables - Other for Regeneron Pharmaceuticals (REGN) over the last 12 years, with Q3 2020 value amounting to $460.8 million.

  • Regeneron Pharmaceuticals' Receivables - Other rose 3341.05% to $460.8 million in Q3 2020 from the same period last year, while for Sep 2020 it was $460.8 million, marking a year-over-year increase of 3341.05%. This contributed to the annual value of $260.6 million for FY2019, which is 1510.6% up from last year.
  • According to the latest figures from Q3 2020, Regeneron Pharmaceuticals' Receivables - Other is $460.8 million, which was up 3341.05% from $389.2 million recorded in Q2 2020.
  • In the past 5 years, Regeneron Pharmaceuticals' Receivables - Other ranged from a high of $468.3 million in Q1 2020 and a low of $93.0 million during Q4 2016
  • Its 5-year average for Receivables - Other is $249.8 million, with a median of $226.4 million in 2018.
  • Its Receivables - Other has fluctuated over the past 5 years, first tumbled by 3928.32% in 2016, then surged by 10830.42% in 2017.
  • Regeneron Pharmaceuticals' Receivables - Other (Quarter) stood at $93.0 million in 2016, then soared by 108.3% to $193.7 million in 2017, then increased by 16.88% to $226.4 million in 2018, then grew by 15.11% to $260.6 million in 2019, then soared by 76.82% to $460.8 million in 2020.
  • Its last three reported values are $460.8 million in Q3 2020, $389.2 million for Q2 2020, and $468.3 million during Q1 2020.